Penobscot Investment Management Company Inc. Grows Stock Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Penobscot Investment Management Company Inc. grew its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 2,430 shares of the medical equipment provider’s stock after purchasing an additional 75 shares during the period. Penobscot Investment Management Company Inc.’s holdings in Intuitive Surgical were worth $970,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ISRG. Brookstone Capital Management lifted its position in Intuitive Surgical by 20.3% in the 4th quarter. Brookstone Capital Management now owns 8,736 shares of the medical equipment provider’s stock worth $2,947,000 after buying an additional 1,477 shares during the last quarter. GPS Wealth Strategies Group LLC raised its stake in shares of Intuitive Surgical by 39.9% during the fourth quarter. GPS Wealth Strategies Group LLC now owns 1,107 shares of the medical equipment provider’s stock worth $373,000 after acquiring an additional 316 shares in the last quarter. Premier Path Wealth Partners LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth approximately $913,000. Rosenberg Matthew Hamilton boosted its stake in shares of Intuitive Surgical by 21.9% in the 4th quarter. Rosenberg Matthew Hamilton now owns 345 shares of the medical equipment provider’s stock valued at $116,000 after purchasing an additional 62 shares in the last quarter. Finally, Wealthsource Partners LLC bought a new position in shares of Intuitive Surgical during the 4th quarter valued at $207,000. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have weighed in on the stock. Morgan Stanley boosted their price target on shares of Intuitive Surgical from $375.00 to $460.00 and gave the stock an “equal weight” rating in a research note on Monday, July 15th. The Goldman Sachs Group initiated coverage on Intuitive Surgical in a research note on Thursday, May 30th. They issued a “buy” rating and a $500.00 target price for the company. JPMorgan Chase & Co. increased their target price on Intuitive Surgical from $475.00 to $495.00 and gave the company an “overweight” rating in a report on Friday. Citigroup lifted their price target on Intuitive Surgical from $462.00 to $512.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Finally, BTIG Research boosted their price objective on Intuitive Surgical from $451.00 to $459.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and a consensus target price of $438.74.

Insider Buying and Selling

In other Intuitive Surgical news, Director Craig H. Barratt sold 2,496 shares of the firm’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total transaction of $1,005,613.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Intuitive Surgical news, Director Mark J. Rubash sold 1,709 shares of the firm’s stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $380.00, for a total transaction of $649,420.00. Following the completion of the transaction, the director now owns 16,051 shares of the company’s stock, valued at $6,099,380. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Craig H. Barratt sold 2,496 shares of the business’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $402.89, for a total value of $1,005,613.44. The disclosure for this sale can be found here. Insiders have sold a total of 10,638 shares of company stock valued at $4,214,441 over the last ninety days. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of NASDAQ ISRG traded down $4.13 during midday trading on Tuesday, hitting $456.99. 1,251,616 shares of the company traded hands, compared to its average volume of 1,553,944. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $468.78. The firm has a market cap of $162.09 billion, a P/E ratio of 82.65, a P/E/G ratio of 5.87 and a beta of 1.39. The stock has a 50-day moving average price of $423.65 and a 200 day moving average price of $395.69.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping analysts’ consensus estimates of $1.54 by $0.24. The firm had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.18 EPS. As a group, equities analysts expect that Intuitive Surgical, Inc. will post 4.8 earnings per share for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.